文献速递白血病造血干细胞移植与细胞治疗

基因型对克拉屈滨联合阿糖胞苷治疗复发难治性急性髓系白血病的影响:一项回顾性研究

Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.
PubMed 文献 · Br J Haematol · 2019-06-18

该单中心回顾性研究纳入34例复发难治性急性髓系白血病(R/R AML)患者,采用克拉屈滨联合阿糖胞苷(CLARA)方案治疗。不良核型与缓解或生存无关,低突变负荷和无剪接突变与延长生存相关。

要点

  • 不良核型与缓解或生存无相关性,继发性AML在缓解者中更常见。
  • 低突变负荷和无剪接突变与CLARA治疗后延长生存相关。

核心结论

  • CLARA方案在R/R AML患者中具有较好的疗效和安全性平衡,不良核型不影响缓解或生存,低突变负荷和无剪接突变与延长生存相关。

研究设计与样本

  • 单中心回顾性研究,纳入34例接受CLARA方案治疗的复发难治性急性髓系白血病患者,重点关注队列的遗传学特征。

主要发现

  • 不良核型与缓解或生存无相关性,继发性AML在CLARA缓解者中更常见。
  • 低突变负荷和无剪接突变与CLARA治疗后延长生存相关。

临床怎么用

  • CLARA方案可用于R/R AML患者的挽救治疗, regardless of adverse prognostic markers。
  • 广泛基因分型可能对R/R AML的预后判断有意义。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains a challenge. Among salvage chemotherapy regimens, the clofarabine and cytarabine (CLARA) combination has been widely evaluated and has a favourable safety/efficacy balance. Predictive factors of efficacy in patients with R/R AML are unclear, particularly the impact of AML-related gene mutations. We report our single-centre experience on 34 R/R AML patients treated with CLARA, with a focus on the genetic characterization of our cohort. CLARA yielded a 47% response rate among this poor-prognosis AML population, while two patients (5·8%) died due to treatment-related toxicity. The two-year progression-free survival and overall survival rates were 29·4% and 35·3%, respectively. Nine patients (26%) had long-term response with a median follow-up of 39·5 months among the responders, of whom six underwent haematopoietic stem cell transplantation. Adverse karyotype did not correlate with response or survival, and secondary AML were more frequent among responders to CLARA, suggesting that this combination may successfully salvage R/R AML patients regardless of adverse prognostic markers. We also observed that a low mutational burden and absence of splice mutations correlated with prolonged survival after CLARA, suggesting that extensive genotyping may have prognostic implications in R/R AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mondesir J, Alary AS, Sibon D, et al. Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study. Br J Haematol. 2019. PMID: 31215036. doi:10.1111/bjh.16045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。